Breaking AI & Tech News Analyzed

A recent Cochrane review analyzing 17 clinical trials involving over 20,000 people with mild cognitive impairment or dementia has concluded that anti-amyloid drugs have a 'trivial' effect on cognition and dementia severity over 18 months.The review, which assessed seven anti-amyloid drugs, found that improvements in functional ability were 'small at best' and that the drugs caused more swelling and bleeding in the brain than the placebo.The findings are a blow to the new wave of drugs designed to slow Alzheimer's by clearing clumps of amyloid protein that build up in the brain. Despite initial hype, with some regulators approving drugs like lcanemab and donanemab, many countries have stopped short of providing them through public health services due to concerns over their effectiveness and cost.Critics of the review argue that it combines results from older, failed drugs with those from newer, more effective medicines, which may skew the conclusions. However, the review's authors defend their approach, stating that all the drugs aimed to remove amyloid from the brain and assessed the impact on patients in a similar way.The review's lead author, Edo Richard, notes that the effect sizes are too small for patients and caregivers to notice, and that the drugs are also 'burdensome' due to the need for regular intravenous drug infusions and MRI scans.Experts in the field, such as Robert Howard, express concerns that the drugs may not truly alter the course of Alzheimer's, and that it's unfair to raise expectations in patients. Meanwhile, Alzheimer's Research UK argues that the review's conclusions are limited by its methodology and that anti-amyloid treatments will not be the whole answer to curing Alzheimer's.

Pet owners in Britain may soon be barred from purchasing flea‑control products for cats and dogs at local shops. The government has opened an eight‑week public consultation to consider restricting sales to veterinarians or pharmacists, arguing that professional oversight will ensure correct usage and reduce environmental harm. Current regulations allow these topical treatments—containing potent insecticides such as fipronil and imidacloprid—to be bought in any pet store. Once applied, the chemicals disperse into the animal’s fur, enter waterways through washing or swimming, and have been linked to songbird nest failures and massive bee mortality. Water minister Emma Hardy emphasized the government’s commitment to “restore nature and clean up our rivers,” noting that while the products are vital for pet health, their distribution should be limited to professionals who can advise on safe application. Research funded by the Veterinary Medicines Directorate (VMD) found that pet owners’ use of these treatments contributes to detectable levels of fipronil and imidacloprid in rivers and lakes. Environment Agency data reveal fipronil residues in 98% of water samples and imidacloprid in 66%, often exceeding toxicity thresholds for aquatic insects. One monthly flea treatment for a large dog contains enough imidacloprid to kill 25 million bees, underscoring the broader impact on pollinator populations. In the UK, fipronil is an ingredient in 66 veterinary products, while imidacloprid appears in 21. Abigail Seager, chief executive of the Veterinary Medicines Directive, acknowledged the dual role of these chemicals in protecting pets and people from parasites, but warned that “they are entering our waterways and may be having wider environmental impacts.” She called for diverse stakeholder input to balance medicine availability with ecological protection. The consultation follows a recent governmental pledge to ban imidacloprid and two other neonicotinoids—clothianidin and thiamethoxam—from agricultural use, reflecting a broader strategy to safeguard biodiversity.

The ongoing conflict between the US and Iran has taken a turn for the worse, with President Trump's decision to escalate rather than negotiate turning this into a global problem. Europe, which had initially adopted a stance of non-involvement, is now facing the consequences of Trump's actions. The US naval blockade of Iran aims to prevent the country from shipping oil to market unless it allows free passage through the Strait of Hormuz. However, this move has caused oil prices to rise and stocks to fall, with the global economy feeling the pinch. The International Monetary Fund (IMF) meeting in Washington has turned into a crisis summit, with global growth forecasts being revised down due to the expected prolonged energy shock. The conflict has also raised concerns about shortages of essential goods such as medicines, fertilizers, and helium, which could have far-reaching consequences for the global economy. The article suggests that Trump's threats to stop tankers reaching Iranian ports and seize any ship paying Iran a toll for safe passage risk spiraling the war out of control. In this context, former UK Prime Minister Boris Johnson's suggestion that Europe should help the US get out of the mess it has created has some merit. The article argues that Europe needs to find a way to help Trump retreat without losing face, and that diplomacy and negotiation are crucial to resolving the crisis. The article concludes that Trump's war aims are unpredictable and that the US needs NATO's diplomats and ideas to resolve the crisis, rather than just brute force. Europe must find a way to work with the US to end the conflict and prevent further economic damage.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.

As the deadline set by US President Donald Trump for Iran to reopen the Strait of Hormuz approaches, Iranians are bracing for a potential catastrophe. With over 90 million people facing uncertainty, daily life in Iran could drastically change by Wednesday.Trump has issued ominous warnings, stating that if Iran does not comply, its electricity, bridges, and other critical infrastructure will be targeted, despite this violating international law. Such actions could lead to the destruction of a whole civilisation, as Trump previously mentioned.In the hours leading up to the 8pm US Eastern Time (23:00 GMT) deadline, residents of Tehran express their fears. A Tehran resident noted, “We all know he’s crazy enough to do it. He doesn’t care as long as he believes it serves his interest.” This sentiment reflects the anxiety gripping the nation as the threat of an attack looms.Preparations for potential blackouts and shortages are underway. Iranians are charging phones and power banks, using household appliances, and stocking up on essentials like bread, flour, and bottled water. The price of bottled water has surged due to chronic inflation and the ongoing conflict.The impact on vulnerable populations, including the sick and disabled, could be severe. Long-lasting power cuts would hinder access to essential medicines and medical equipment, exacerbating the crisis.Market prices for electrical devices and generators have skyrocketed, with many struggling to afford these necessities. A resident from the northern province of Gilan shared that he purchased a generator to power essential items, spending nearly all his earnings.Despite the threats, there is some optimism about Iran’s decentralised power distribution system potentially mitigating damage. The Ministry of Energy assured the public that they are prepared for worst-case scenarios and urged calm.The Islamic Revolutionary Guard Corps (IRGC) announced readiness to expand its target list and attack critical infrastructure in neighbouring countries if the threatened attacks proceed. Iranian politicians, including former President Hassan Rouhani, have condemned Trump’s statements, highlighting Iran’s resilience and cultural heritage.As the situation unfolds, protests and demonstrations are taking place across the country. State-backed motorcades are roaming the streets of Tehran, playing revolutionary songs, while armed checkpoints maintain control over highways and public spaces.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

President Donald Trump has taken a significant step to push for pharmaceutical deals by signing an executive order that could impose tariffs of up to 100% on some patented drugs. This move is part of his administration's effort to secure lower prices for medicines.Under the executive order, companies that have signed a 'most favoured nation' pricing deal and are actively building facilities in the US will have a zero-percent tariff. For those that don't have a pricing deal but are building such projects in the US, a 20 percent tariff will apply, but it will increase to 100 percent in four years.A senior administration official stated that companies still have months to negotiate before the 100 percent tariffs kick in. Bigger companies will have 120 days, and 180 days are offered for everyone else.The administration has already reached 17 pricing deals with major drugmakers, 13 of which have signed. The executive order aims to address the threatened impairment of national security posed by imports of pharmaceuticals and pharmaceutical ingredients.Critics, pharmaceutical leaders, and medical groups have warned of the consequences the new tariffs could bring, including increased costs and potential jeopardy to billions in US investments. The pharmaceutical company trade group PhRMA has expressed concerns that taxes on cutting-edge medicines will increase costs and could jeopardize investments.

The ongoing closure of the Strait of Hormuz, a crucial oil and gas shipping route blocked by Iran since the US-Israeli attacks began, is having ripple effects around the world. If the strait remains closed, transport blockages across the Middle East could cause significant shocks to food and medicine supplies in the UK.UK Foreign Secretary Yvette Cooper is hosting a meeting with 35 other countries to discuss reopening the strait. Experts warn that a prolonged closure could lead to food price inflation doubling in England and medicine shortages due to disrupted supply chains.Impact on Food SuppliesProf Tim Lang from City St George's, University of London, warns that 'all bets are off' for food supplies if the crisis continues. Rising fossil fuel prices will impact food transportation and production, as fuel is used to transport food and produce fertilizers and other inputs.The farming sector is already facing problems, with dairy production hit due to delayed fertilizer purchases and salad vegetable and dairy producers facing disruptions. Iranian imports like pistachios and saffron are also affected.Impact on Medicine SuppliesWhile there's no hard evidence of medicine shortages yet, price increases are being seen, which can signal disruptions in the medicine supply chain. Iran does not manufacture many medicines but affects the sector through rising energy costs and transport links between major pharmaceutical-producing countries and the UK.David Weeks from Moody's notes that shortages are driven by delays in petrochemical precursors for active pharmaceutical ingredients. Medicine stockpiles in European countries, including the UK, can last up to six months, but long-term conflicts could lead to more severe shortages.